一款每三个月仅需注射一次的新型降脂药,在获得美国FDA批准后不到三个月,其中国上市进程就已紧密启动,这背后是跨国药企在中国市场战略的一次深刻转型。 2025年11月,全球首个针对APOC3的siRNA药物Plozasiran获得美国FDA批准,在饮食控制基础上,用于降低家族性乳糜微粒血症综合征(FCS)成人患者的甘油三酯水平。这款由Arrowhead(箭头制药)开发的创新疗法,仅需每三个月...
Source Link一款每三个月仅需注射一次的新型降脂药,在获得美国FDA批准后不到三个月,其中国上市进程就已紧密启动,这背后是跨国药企在中国市场战略的一次深刻转型。 2025年11月,全球首个针对APOC3的siRNA药物Plozasiran获得美国FDA批准,在饮食控制基础上,用于降低家族性乳糜微粒血症综合征(FCS)成人患者的甘油三酯水平。这款由Arrowhead(箭头制药)开发的创新疗法,仅需每三个月...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.